Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoGenex Pharmaceuticals, Inc. (noting a discrepancy with the metadata company name "ACHIEVE LIFE SCIENCES, INC.") on May 30, 2009. The registrant is a Delaware corporation headquartered in Bothell, Washington. The report serves as a Regulation FD disclosure regarding the issuance of two press releases concerning clinical trial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory disclosure of clinical trial announcements rather than financial performance data.
Material Changes
The material event reported is the announcement of clinical trial results for two drug candidates on May 30, 2009:
- OGX-011: Announced to provide a survival benefit in a randomized Phase 2 trial for advanced metastatic prostate cancer.
- OGX-427: Announced to demonstrate safety, evidence of declines in circulating tumor cells, and reductions in tumor markers in a Phase 1 cancer trial.
Guidance, Outlook, and Risks
The filing incorporates press releases by reference but does not contain explicit forward-looking guidance, management commentary on financial outlook, or a detailed risk factor section within the body of the 8-K. The report includes a standard disclaimer stating that the information is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press releases attached as Exhibits 99.1 and 99.2 for detailed statistical data on the survival benefits and safety profiles.
- Confirm the current corporate name and status, as the metadata lists "ACHIEVE LIFE SCIENCES, INC." while the filing is for "ONCOGENEX PHARMACEUTICALS, INC."
- Review subsequent filings to determine if these Phase 1 and Phase 2 results led to Phase 3 trial initiation or regulatory submissions.
- Check the company's most recent 10-K or 10-Q for financial context, as this 8-K contains no financial metrics.